Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-03-12

Clinical Trial Update: Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) [Phase 3]

View source ↗

Summary

A Phase 3 trial update reports on the efficacy and safety of pirfenidone in idiopathic pulmonary fibrosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Esbriet (pirfenidone)

Snippet

Sponsor: Genentech, Inc. | Conditions: Idiopathic Pulmonary Fibrosis | Phase 3 | Status: COMPLETED | Results posted: 2015-03-12